Clinical Trial Update: Safety Analysis of Intravenous Rapid Infusion of Obinutuzumab in Patients With B-cell Non-Hodgkin's Lymphoma in China [Phase 2]

View source ↗

Summary

A Phase 2 safety analysis evaluating intravenous rapid infusion of obinutuzumab in patients with B-cell non-Hodgkin's lymphoma conducted in China.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Obinutuzumab, Rapid Infusion | Phase 2 | Status: UNKNOWN